You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Your guide to maintenance treatment with Zejula (niraparib)

Image showing a graphic of 2 people talking

The information on this site is intended to support the care you receive from your healthcare team. It is important that you speak with them if you have any questions about your treatment or have any side effects.

Here, you will find a few resources to help guide your maintenance treatment with Zejula, and help you feel comfortable and hopefully, more in control of your care.

Learn more about your Zejula maintenance treatment


Your guide to maintenance treatment with Zejula

The patient information booklet includes tips and resources to help you keep on top of your treatment.

Please click here to download the Zejula patient information booklet.

If you have any questions about your maintenance treatment, please speak to a member of your healthcare team who will be able to help you further.

This information is specifically for women who have been prescribed Zejula (niraparib). If you have not been prescribed Zejula, please return to the Public website.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side affects you may get.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store.
Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.